CRISPR Therapeutics AG
Formerly Inception Genomics AG
CRISPR Therapeutics AG is listed today as CRISPR Therapeutics AG: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $1 M | Private placement after listing | Under $2 million | equity | SEC | |
| Oct 2016 | $35 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company CRISPR Therapeutics AG, its revenue in fiscal 2025 came from these product and service lines: Grant Revenue $3.51 million (100%).
Annual report (SEC XBRL) · Dec 2025
CRISPR Therapeutics AG chose not to state its revenue in its newest notice of a funding round (Apr 2020).
SEC Form D · Apr 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2020
Products and services#
No products or services of CRISPR Therapeutics AG are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Celgene Corp /de/ | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Hadley Harbor Master Investors (Cayman) L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Sven Ante Lundberg | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2016) | SEC Form 3 |
| Versant Affiliates Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Ophthalmic Affiliates I, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Side Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Venture Capital IV, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Venture Capital V (Canada), LP | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Venture Capital V, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.
Largest shareholders today
Institutions holding CRISPR Therapeutics AG shares, as of Sep 30, 2026.
- ARK Investment Management LLC$556 M10.37%
- BlackRock, Inc.$459 M8.56%
- State Street Corp$276 M5.15%
- Capital World Investors$262 M4.89%
- Orbis Allan Gray Ltd$250 M4.66%
- GSK plc$144 M2.69%
- Geode Capital Management, LLC$139 M2.59%
- SR One Capital Management, LP$113 M2.10%
- Two Sigma Investments, LP$112 M2.08%
- FMR LLC$105 M1.96%
- Bank Of America Corp /de/$96 M1.79%
- T. Rowe Price Investment Management, Inc.$92 M1.71%
- Sumitomo Mitsui Trust Group, Inc.$80 M1.50%
- Amova Asset Management Americas, Inc.$80 M1.50%
- EcoR1 Capital, LLC$77 M1.43%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James Kasinger | Executive officer | Apr 2020 |
| Lawrence Klein | Executive officer | Apr 2020 |
| Michael Tomsicek | Executive officer | Apr 2020 |
| Rodger Novak | Executive officer | Apr 2020 |
| Samarth Kulkarni | Executive officer | Apr 2020 |
| Tony Ho | Executive officer | Apr 2020 |
| Kala Ante Subramanian | Executive officer | Nov 2016 |
| Marc J. Becker | Executive officer | Nov 2016 |
| Samarth Ante Kulkarni | Executive officer | Nov 2016 |
| Sven Ante Lundberg | Executive officer | Nov 2016 |
| Tyler Ante Dylan-Hyde | Executive officer | Nov 2016 |
| Ali Behbahani | Director | Apr 2020 |
| Bradley Bolzon | Director | Apr 2020 |
| John Greene | Director | Apr 2020 |
| Katherine High | Director | Apr 2020 |
| Rodger Novak | Director | Apr 2020 |
| Samarth Kulkarni | Director | Apr 2020 |
| Simeon George | Director | Apr 2020 |
| Ali Anthony Behbahani | Director | Nov 2016 |
| Bradley Anthony Bolzon | Director | Nov 2016 |
| Kurt J. von Emster | Director | Nov 2016 |
| N. Anthony Coles | Director | Nov 2016 |
| Pablo J. Cagnoni | Director | Nov 2016 |
| Simeon J. George | Director | Nov 2016 |
| Thomas J. Woiwode | Director | Nov 2016 |
About
Company in Basel, Switzerland.
Went public since 2016. Its SEC number is that of a company listed on a stock exchange.